Close Menu

Helomics

The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.

Through the deal, Helomics aims to build a predictive model of prostate cancer drug response based on a combination of genomic and spectroscopy data.

The companies will use their respective technologies in a study investigating the associations between ovarian cancer and the gut microbiome.

Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.

Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.

The assay is based on Ariel's Smart-MD bioinformatics platform, which combines patient symptoms and history with next-generation sequencing data.

The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.

Skyline will use Helomics' D-Chip bioinformatics repository of more than 149,000 tumors to develop cancer diagnostics.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.